{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042572","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2023-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.567061+00:00","generated_at":"2026-06-11T09:37:18.847528+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SeaStar Medical Q2 net loss widens to $3.7M; cash at $13K; FDA setback on pediatric device","bullets":["Net loss $3.7M ($0.25/sh) vs $0.9M ($0.12) in Q2 2022; R&D up to $2.0M, G&A $1.7M.","Cash only $13K as of June 30; raised $3.3M convertible debt in March, $2.2M in May, $543K note in August.","FDA HDE application for pediatric SCD-PED not approvable; working with FDA for resubmission.","Two sites activated for adult NEUTRALIZE-AKI trial; expects SCD-ADULT approval H1 2025, launch H2 2025.","Business update call on Aug 22, 2023 at 4pm ET."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042572","json":"https://secwatch.observer/filing/0000950170-23-042572.json","markdown":"https://secwatch.observer/filing/0000950170-23-042572.md","text":"https://secwatch.observer/filing/0000950170-23-042572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000095017023042572/0000950170-23-042572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000095017023042572/icu-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:37:18.847528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5868e7d5337ad1cecef4ee2a56d0cfb823249729","claim":"SeaStar Medical Holding Corp reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, SeaStar Medical Holding Corporation (the “Company”) issued a press release announcing its financial condition and results of operations for the fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017023042572/0000950170-23-042572-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}